Stock Analysis
Xencor, Inc. (XNCR) Stock Analysis
Xencor, Inc. (XNCR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Xencor, Inc. (XNCR) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 78/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
XNCR at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $29.82 |
| AIQ Score | 52/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.07B |
| P/E Ratio (TTM) | -12.86 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.29 |
| Revenue (quarter ended 2026-06-30) | $51.22M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.84 |
| Volume | 1.29M |
| 52-week range | $10.38-$33.60 |
| RSI 14 | 67.53 |
| 50-Day SMA | $25.68 |
| 200-Day SMA | $16.88 |
| Analyst Price Target | $34.40 |
| Next Earnings | Nov 4, 2026 |
XNCRXencor, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum78
- Value34
- Quality48
- Risk resilience55
- Sentiment67
XNCR Stock Analysis Summary
Xencor, Inc. (XNCR) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 78/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, XNCR has AIQ Score of 52/100 with Momentum base of 78/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Momentum (78/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.09% stock move · XNCR classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is XNCR Bullish or Bearish Right Now?
XNCR currently has a neutral overall setup. Momentum is the strongest factor at 78/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 78/100.
- - Price is +13.73% above its 50-day SMA.
- - Analyst target implies +15.36% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 4).
- - Value is the current constraint at 34/100.
Current Consensus
XNCR's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 5 neutral, and 4 sell votes. XNCR's 14-day RSI is 67.53, which places the stock in a constructive momentum range. XNCR's beta is 0.84, indicating market sensitivity broadly in line with the market.
What Changed in XNCR?
The largest recent change in XNCR is Momentum moving up by 11.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the XNCR Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
XNCR Decision Framework
Public evidence layers, setup checks, and risk context for Xencor, Inc..
Xencor, Inc. (XNCR) Stock Analysis
Xencor, Inc. has an AIQ Score of 52/100 in a Neutral regime. Momentum is strongest at 78/100. Beta is 0.9, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | XNCR is in a Neutral AIQ regime with score 52/100. |
| Signal Conflict | The primary conflict is that momentum leads at 78/100 while value lags at 34/100. |
| Factor Evidence | Momentum 78/100 · Value 34/100 · Quality 48/100 · Risk 55/100 · Sentiment 67/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 78/100.
Momentum is 78/100 and RSI (14) is 67.5.
XNCR is in a Neutral regime at 52/100.
Risk factor is 55/100 with beta 0.9 and annual volatility 64.13%.
Current conflict: momentum leads at 78/100 while value lags at 34/100.
XNCR Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
XNCR Fundamentals
XNCR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
XNCR Technical Analysis
XNCR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
XNCR Stock Catalysts
Track XNCR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
XNCR Dividend Analysis
XNCR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
XNCR Financial Data
XNCR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
XNCR Risk Analysis
XNCR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
XNCR Stock News
XNCR stock news, market tone, recent headlines, and catalyst context.
XNCR vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: XNCR · ACAD · ALNY · ARWR · BDTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| XNCR Current stock | 52/100 | 34/100 | 78/100 | 55/100 | 1.33 | 64.13% | Current |
| ACAD Acadia Pharmaceuticals | 68/100 | 57/100 | 50/100 | 69/100 | -0.12 | 38.76% | XNCR vs ACAD |
| ALNY Alnylam Pharmaceuticals | 43/100 | 25/100 | 16/100 | 41/100 | -1.65 | 54.27% | XNCR vs ALNY |
| ARWR Arrowhead Pharmaceuticals | 38/100 | 34/100 | 38/100 | 55/100 | 0.9 | 61.76% | XNCR vs ARWR |
| BDTX Black Diamond Therapeutics | 35/100 | — | 43/100 | 37/100 | -0.49 | 81.98% | XNCR vs BDTX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching XNCR
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for XNCR
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
XNCR Stock FAQ
What is XNCR stock price today?
Xencor, Inc.'s current stock price is $29.82. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is XNCR bullish or bearish right now?
XNCR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is XNCR's market cap?
XNCR's market cap is $2.07B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is XNCR's current P/E ratio?
XNCR's current P/E ratio is -12.86 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is XNCR's RSI?
XNCR's 14-day RSI is 67.53 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is XNCR above its 50-day and 200-day moving averages?
XNCR is 13.73% from its 50-day SMA and 73.05% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is XNCR's next earnings date?
XNCR's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does XNCR pay a dividend?
XNCR's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.